Skip to main content
SpringerLink
Log in

Skin inflammation

  • Chapter
In Vivo Models of Inflammation

Part of the book series: Progress in Inflammation Research ((PIR))

Abstract

Inflammation is a component of many skin disorders including psoriasis, atopic dermatitis, contact sensitivity and acne [1–3]. These diseases collectively affect over 20% of the population and dermatologists have developed many different treatment plans. Topical corticosteroids have been mainstay therapies since their introduction in 1952 [4, 5]. While these powerful anti-inflammatory drugs produce good resolution of both acute and chronic skin inflammation, long-term treatment in chronic diseases such as psoriasis are not feasible due to side-effects. Topical steroids induce skin atrophy which limits the time of treatment [6]. Also, application of topical steroids to large body surface areas results in hypothalamic-pituitary-adrenal suppression due to systemic absorption thus requiring the withdrawal of treatment. In these cases the disease rebounds sometimes in a form more severe than before the treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 74.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. US National Health Survey (1971–1974) Vital and Health Statistics Series II,No. 212

    Google Scholar 

  2. Schultz LF (1993) The epidemiology of atopic dermatitis. Monogr Allergy 31: 9–28

    Google Scholar 

  3. Menne T, Christopherson J, Maibach HI (1987) Epidemiology of allergic contact sensitization. Monogr Allergy 21: 132–161

    PubMed  CAS  Google Scholar 

  4. Sulzberger MB, Witten VI-I (1952) Effect of topically applied compound F in selected dermatoses. J Invest Dermatol 19: 101–102

    PubMed  CAS  Google Scholar 

  5. Schlagel CA (1965) Comparative efficacy of topical anti-inflammatory corticosteroids. J Pharm Sci 54: 335–354

    Article  PubMed  CAS  Google Scholar 

  6. Kligman AM (1988) Adverse effects of topical corticosteroids. In: E Christophers, E Schopf, AM Kligman (eds): Topical corticosteroid therapy. A novel approach to safer drugs. Raven Press, New York, 181–187

    Google Scholar 

  7. Hammerstrom S, Hamberg M, Samuelsson B, Duell E, Voorhees JJ (1975) Increased concentrations of non-esterified arachidonic acid, 12-HETE, prostaglandin E2, prostaglandin Fla in epidermis of psoriasis. Proc Natl Acad Sci USA 72: 5130–5134

    Article  Google Scholar 

  8. Brain S, Camp RDR, Dowd P, Black A, Woollard P, Mallet A, Greaves M (1982) Psoriasis and leukotriene B4. Lancet 2: 762–763

    Article  PubMed  CAS  Google Scholar 

  9. Samuelsson B (1987) An elucidation of the arachidonic acid cascade. Discovery of prostaglandins, thromboxane and leukotrienes. Drugs 33: 2–9

    Article  PubMed  CAS  Google Scholar 

  10. Irvine RF (1982) How is the level of free arachidonate controlled in mammalian cells. Biochem J 204: 3–16

    PubMed  CAS  Google Scholar 

  11. Marshall LA, Mayer RJ (1995) Phospholipase A2 isoforms as novel drug targets. In: RR Ruffolo, MA Hollinger (eds): Inflammation, mediators and pathways. CRC Press, Boca Raton, 1–22

    Google Scholar 

  12. Trancik RJ, Lowe NJ (1985) Evaluation of topical non-steroidal anti-inflammatory drugs. In: HI Maibach, NJ Lowe (eds): Models in dermatology, Vol 2, Karger, Basel, 35–42

    Google Scholar 

  13. Tonelli G, Thibault L, Ringler I (1965) A bioassay for the concomitant assessment of antiphlogistic and thymolytic activities of topically applied corticosteroids. Endocrinology 77: 625–634

    Article  PubMed  CAS  Google Scholar 

  14. Kuehl FA, Humes JL, Egan RW, Ham EA, Beveridge GC, Van Arman CG (1977) Role of prostaglandin endoperoxide PGG2 in inflammatory processes. Nature 265: 170–173

    Article  PubMed  CAS  Google Scholar 

  15. Young JM, Wagner BM, Spires DA (1983) Tachyphylaxis in 12-O-tetradecanoylphorbol acetate and arachidonic acid induced ear edema. J Invest Dermatol 80: 48–52

    Article  PubMed  CAS  Google Scholar 

  16. Rao TS, Currie JL, Shaffer AF, Isakson PC (1993) Comparative evaluation of arachidonic acid and TPA-induced dermal inflammation. Inflammation 17: 723–741

    Article  PubMed  CAS  Google Scholar 

  17. DeYoung LM, Kheifets JB, Ballaron SJ, Young JM (1989) Edema and cell infiltration in the phorbol ester-treated mouse ear are temporally separate and can be differentially modulated by pharmacologic agents. Agents Actions 26: 335–341

    Article  CAS  Google Scholar 

  18. Fuerstenberger G, Marks F (1982) Early prostaglandin E synthesis is an obligatory event in induction of cell proliferation in mouse epidermis in vivo by TPA. Biochem Biophys Res Comm 92: 749–756

    Google Scholar 

  19. Carlson RP, Oneill-Davis L, Chang J, Lewis AJ (1985) Modulation of mouse ear edema by cyclooxygenase and lipoxygenase inhibitors and other pharmacologic agents. Agents Actions 17: 197–204

    Article  PubMed  CAS  Google Scholar 

  20. Rao TS, Yu SS, Djuric SW, Isakson PC (1994) Phorbol ester-induced dermal inflammation in mice: evaluation of inhibitors of 5-lipoxygenase and antagonists of LTB4 receptor. J Lipid Mediat Cell Signal 10: 213–228

    PubMed  CAS  Google Scholar 

  21. Tramposch KM, Steiner SA, Stanley PL, Nettleton DO, Franson RC, Lewin AH, Carroll FI (1992) Novel inhibitor of phospholipase A2 with topical anti-inflammatory activity. Biochem Biophys Res Comm 189: 272–279

    Article  CAS  Google Scholar 

  22. Burley ES, Smith B, Cutter G, Ahlem JK, Jacobs RS (1982) Antagonism of TPA-induced inflammation by the natural product manoalide. Pharmacologist 24: 117

    Google Scholar 

  23. Wershil BK, Murakami T, Galli SJ (1988) Mast cell-dependent amplification of an immunologically non-specific inflammatory response. Mast cells are required for the full expression of cutaneous acute inflammation induced by TPA. J Immunol 140: 2356–2360

    Google Scholar 

  24. Kern AB (1966) Indomethacin for psoriasis. Arch Dermatol 93: 239–240

    Article  PubMed  CAS  Google Scholar 

  25. Green CA, Schuster S (1987) Lack of effect of topical indomethacin on psoriasis. Br J Clin Pharmacol 24: 381–384

    Article  PubMed  CAS  Google Scholar 

  26. Katayama H, Kawada A (1981) Exacerbation of psoriasis induced by indomethacin. J Dermatol 8: 323–327

    PubMed  CAS  Google Scholar 

  27. Crummey A, Harper GP, Boyle EA, Mangan FR (1987) Inhibition of arachidonic acid-induced ear edema as a model for assessing topical anti-inflammatory compounds. Agents Actions 20: 69–76

    Article  PubMed  CAS  Google Scholar 

  28. Puignero V, Queralt J (1997) Effect of topically applied cyclosporine A on arachidonic acid-and TPA-induced dermal inflammation in mouse ear. Inflammation 21: 357–369

    Article  PubMed  CAS  Google Scholar 

  29. Stanley PL, Steiner S, Havens M, Tramposch KM (1991) Mouse skin inflammation induced by multiple topical application of 12-O-tetradecanoyphorbol-13-acetate. Skin Pharmacol 4: 262–271

    Article  PubMed  CAS  Google Scholar 

  30. Alford JG, Stanley PL, Todderud G, Tramposch KM (1992) Temporal infiltration of leukocyte subsets into mouse skin inflamed with phorbol ester. Agents Actions 37: 260–267

    Article  PubMed  CAS  Google Scholar 

  31. Norris JFB, Iderton E, Yardley HJ, Summerly R, Forster S (1984) Utilization of epidermal phospholipase A2 inhibition to monitor topical steroid action. Br J Dermatol III (Suppl 27 ): 195–203

    Google Scholar 

  32. Bresnick E, Bailey G, Bonney RJ, Wightman P (1981) Phospholipase activity in skin after application of phorbol ester and 3-methyl cholanthrene. Carcinogenesis 2: 1119–1122

    Article  PubMed  CAS  Google Scholar 

  33. Tramposch KM, Chilton FH, Stanley PL, Franson RC, Havens MB, Nettleton DO, Dayem LB, Darling IM, Bonney RJ (1994) Inhibitor of phospholipase A2 blocks eicosanoid and platelet activating factor biosynthesis and has topical anti-inflammatory activity. J Pharmacol Expt Therap 271: 852–859

    CAS  Google Scholar 

  34. Christophers E (1996) The immunopathology of psoriasis. Int Arch Allergy Immunol 110: 199–206

    Article  PubMed  CAS  Google Scholar 

  35. Dvorak HF, Galli SJ, Dvorak AM (1986) Cellular and vascular manifestations of cell mediated immunity. Human Pathology 17: 122–137

    Article  PubMed  CAS  Google Scholar 

  36. Crowle AJ (1975) Delayed hypersensitivity in the mouse. Adv Immunol 20: 197–264

    Article  PubMed  CAS  Google Scholar 

  37. Chapman JR, Ruben Z, Butchko GM (1986) Histology of and quantitative assays for oxazolone-induced allergic contact dermatitis in mice. Am J Dermatopathol 8: 130–138

    Article  PubMed  CAS  Google Scholar 

  38. Kondo S, Beissert S, Wang B, Fujisawa H, Kooshesh F, Stratigas A, Granstein RD, Mak TW, Sauder DN (1996) Hyporesponsiveness in contact hypersensitivity and irritant contact dermatitis in CD4 gene targeted mouse. J Invest Dermatol 106: 993–1000

    Article  PubMed  CAS  Google Scholar 

  39. Mosmann TR, Coffman RL (1980) Th1 and Th2 cells: differential patterns of lymphokine secretion lead to different functional properties. Ann Rev Immunol 17: 145–173

    Google Scholar 

  40. Mohler KM, Butler LD (1990) Differential production of IL-2 and IL-4 mRNA in vivo after primary sensitization. J Immunol 145: 1734–1739

    PubMed  CAS  Google Scholar 

  41. Thomson JA, Troutt AB, Kelso A (1993) Contact sensitization to oxazolone: involvement of both interferon y and IL-4 in oxazolone specific Ig and T-cell responses. Immunology 78: 185–192

    PubMed  CAS  Google Scholar 

  42. Bailey SC, Asghar F, Przekop PA, Kurtz ES (1995) A novel contact hypersensitivity model for rank ordering formulated corticosteroids. Inflamm Res 44 (Suppl 2): 5162–5163

    Article  Google Scholar 

  43. Back O, Egelrud T (1985) Topical glucocorticoids and suppression of contact sensitivity. A mouse bioassay of anti-inflammatory effects. Br J Dermatol 112: 539–545

    Article  PubMed  CAS  Google Scholar 

  44. Cavey D, Bouclier M, Burg G, Delamadeleine F, Hensby CN (1990) The pharmacological modulation of delayed-type hypersensitivity reactions to topical oxazolone in mouse skin. Agents Actions 29: 65–67

    Article  PubMed  CAS  Google Scholar 

  45. Rullan PP, Barr RJ, Cole GW (1984) Cyclosporine and murine allergic contact dermatitis. Arch Dermatol 120: 1179–1183

    Article  PubMed  CAS  Google Scholar 

  46. Meingassner JG, Stutz A (1992) Anti-inflammatory effects of macrophilin-interacting drugs in animal models of irritant and allergic contact dermatitis. Int Arch Allergy Immunol 99: 486–489

    Article  CAS  Google Scholar 

  47. Powles AV, Baker BS, Fry L (1989) Cyclosporin A and skin disease. In: AW Thomson (ed): Cyclosporin: mode of action and clinical application. Academic Publishers, Dordrecht, Kluwer, 191–212

    Google Scholar 

  48. Abu-Elmagd K, Van Thiel D, Jegasothy BV, Ackerman CD, Todo S, Fung JJ, Thomson AW, Starzl TE (1991) FK506: a new therapeutic agent for recalcitrant psoriasis. Transplant Proc 23: 3322–3324

    PubMed  CAS  Google Scholar 

  49. Ruzicka T, Bieber T, Schopf E, Rubins A, Dobozy A, Bos JD, Jablonska S, Ahmed I, Thestrup-Pedersen K, Daniel F et al (1997) A short-term trial of tacrolimus ointment for atopic dermatitis. N Engl J Med 337: 816–821

    Article  PubMed  CAS  Google Scholar 

  50. Lauerma AI, Maibach HI, Granlund H, Ercko P, Kartamma M, Stubb S (1992) Inhibition of contact allergy reactions by topical FK-506. Lancet 340: 556

    Article  PubMed  CAS  Google Scholar 

  51. Anderson C (1985) The effect of selected immunomodulating agents on experimental contact reactions. Acta Derm Venerol Suppl 116: 1–48

    CAS  Google Scholar 

  52. Nilsson G, Otto U, Wahlberg JE (1982) Assessment of skin irritancy in man by laser Doppler flowmetry. Contact Dermatitis 8: 401–406

    Article  PubMed  CAS  Google Scholar 

  53. Duncan JI (1994) Differential inhibition of cutaneous T-cell mediated reactions and epidermal cell proliferation by cyclosporin A, FK506 and rapamycin. J Invest Dermatol 102: 84–88

    Article  PubMed  CAS  Google Scholar 

  54. Lauerma AL, Stein BD, Homey B, Lee CH, Bloom E, Maibach HI (1994) Topical FK506: suppression of allergic and irritant contact dermatitis in the guinea pig. Arch Dermatol Res 286: 337–340

    Article  PubMed  CAS  Google Scholar 

  55. Shoji Y, Fukumura T, Kudo M, Yanagawa A, Shimeda J, Mizushima Y (1994) Effect of topical preparation of mycophenolic acid on experimental allergic contact dermatitis of guinea pigs by dinitrofluoro-benzene. J Pharm Pharmacol 46: 643–646

    Article  PubMed  CAS  Google Scholar 

  56. Nakagawa S, Oka D, Jinno Y, Bang D, Veki H (1988) Topical application of cyclosporin on guinea pig allergic contact dermatitis. Arch Dermatol 124: 907–910

    Article  PubMed  CAS  Google Scholar 

  57. Dumont FJ, Staruch MJ, Koprak SL, Melino MR, Sigal NH (1990) Distinct mechanisms of suppression of murine T-cell activation by the related macrolides FK-506 and rapamycin. J Immunol 144: 251–255

    PubMed  CAS  Google Scholar 

  58. Griffiths CEM, Powles AV, Baker BS, Fry L, Valdimarrson H (1987) Topical cyclosporin and psoriasis. Lancet I: 806

    Article  Google Scholar 

  59. Montagna W, Yun JS (1964) The skin of the domestic pig. J Invest Dermatol 43: 11–21

    Google Scholar 

  60. Meyer W, Schwartz R, Neurand K (1978) The skin of domestic mammals as a model for human skin, with special reference to the domestic pig. Current Probl Dermatol 7: 39–52

    CAS  Google Scholar 

  61. Weinstein GD (1965) Autoradiographic studies of the turnover time and protein synthesis in pig epidermis. J Invest Dermatol 44: 413–419

    PubMed  CAS  Google Scholar 

  62. Bissett DL, McBride JF (1983) The use of the domestic pig as an animal model of human dry skin and for comparison of drug and normal skin properties. J Soc Cosmet Chem 34: 317–326

    CAS  Google Scholar 

  63. Barteck MJ, LaBudde JA, Maibach HI (1972) Skin permeability in vivo: comparison of rat, rabbit, pig and man. J Invest Dermatol 58: 114–123

    Article  Google Scholar 

  64. Meingassner JG, Stutz A (1992) Immunosuppressive macrolides of the type FK506: a novel class of topical agents for the treatment of skin diseases? J Invest Dermatol 98: 851–855

    Article  PubMed  CAS  Google Scholar 

  65. Kaidbey KH, Kligman AM (1976) Assay of topical corticosteroids by suppression of experimental rhus dermatitis in humans. Arch Dermatol 112: 808–810

    Article  PubMed  CAS  Google Scholar 

  66. Hermann RC, Taylor RS, Ellis CN (1988) Topical cyclosporin for psoriasis in vitro skin penetration and clinical study. Skin Pharmacology 1: 246–249

    Article  PubMed  CAS  Google Scholar 

  67. Meingassner JG, Grassberger M, Fahrngruber H, Moore HD, Schuurman H, Stutz A (1997) A novel anti-inflammatory drug, SDZ ASM 981, for topical and oral treatment of skin diseases: in vivo pharmacology. Br J Dermatol 137: 568–576

    Article  PubMed  CAS  Google Scholar 

  68. Brown WR, Hardy MH (1988) A hypothesis on the cause of chronic epidermal hyper-proliferation in asebia mice. Clin Exp Dermatol 13: 74–77

    Article  PubMed  CAS  Google Scholar 

  69. Oran A, Marshall JS, Kondo S, Paglia D, McKenzie RC (1997) Cyclosporin inhibits ICAM-1 expression and reduces mast cell numbers in the asebia mouse model of chronic skin inflammation. Br J Dermatol 136: 519–526

    Article  PubMed  CAS  Google Scholar 

  70. Brown WR, Rogozinski TT, Ramsey CA (1988) Anthralin and tar with UVB increase epidermal cell proliferation in asebia mice. Clin Exp Dermatol 13: 248–251

    Article  PubMed  CAS  Google Scholar 

  71. Morita K, Hogan ME, Nanney LB, King LE, Manabe M, Sun TT, Sunberg JP (1995) Cutaneous ultrastructural features of the flaky skin mouse mutation. J Dermatol 22: 385–395

    PubMed  CAS  Google Scholar 

  72. Sunberg JP, Dunstan RW, Roop DR, Beamer WG (1994) Full thickness skin grafts from flaky skin mice to nude mice: maintenance of psoriaform phenotype. J Invest Dermatol 102: 781–788

    Article  Google Scholar 

  73. Nanney LB, Sunberg JP, King LE (1996) Increased epidermal growth factor receptor in fsn/fsn mice. J Invest Dermatol 106: 1169–1174

    Article  PubMed  CAS  Google Scholar 

  74. Nanney LB, Yates RA, King LE (1992) Modulation of epidermal growth factor receptors in psoriatic lesions during treatment with topical EGF. J Invest Dermatol 98: 296–301

    Article  PubMed  CAS  Google Scholar 

  75. HogenEsch H, Gijbels MJJ, Offerman E, van Hooft J, van Bekkum DW, Zurcher C (1993) A spontaneous mutant characterized by chronic proliferative dermatitis in C57BL mice. Am J Pathol 143: 972–982

    PubMed  CAS  Google Scholar 

  76. Gallardo Torres HI, Gijbels MJJ, HogenEsch H, Kraal G (1995) Chronic proliferative dermatitis in mice: neutrophil-endothelium interactions and the role of adhesion molecules. Pathobiology 63: 341–347

    Article  Google Scholar 

  77. Schon M, Detman M, Parker CM (1997) Murine psoriasis-like disorder induced by naive CD4+ T-cells. Nature Med 3: 183–188

    Article  PubMed  CAS  Google Scholar 

  78. Lassus A, Forsstrom S (1985) A dimethoxy-nepthalene derivative (RS43179) compared with 0.025% fluocinolone acetonide gel in the treatment of psoriasis. Br J Dermatol 113: 103–106

    Article  PubMed  CAS  Google Scholar 

  79. Springer DM, Lu BV, D’Andrea SV, Branson JJ, Mansuri MM, Burke JR, Gregor KR, Stanley PL, Tramposch KM (1997) Dicarboxylic acid inhibitors of phospholipase A2. Bioorg Med Chem Lett 7: 793–795

    Article  CAS  Google Scholar 

  80. Barry BW (1983) Dermatological formulation: percutaneous absorption. Marcel Dekker, New York

    Google Scholar 

  81. Schaefer H, Zesch A, Stuttgen G (1982) Skin permeability. Springer Verlag, New York

    Book  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Bristol-Myers Squibb Pharmaceutical Research Institute, 100 Forest Avenue, Buffalo, NY, 14213, USA

    Kenneth M. Tramposch

Authors
  1. Kenneth M. Tramposch
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Cancer Research, Abbott Laboratories, D-47J AP9, 60064, Abbott Park, IL, USA

    Douglas W. Morgan Ph.D. (Senior Group Leader) (Senior Group Leader)

  2. Department of Immunology, SmithKline Beecham Pharmaceuticals, P.O. Box 1539, 19406, King of Prussia, PA, USA

    Lisa A. Marshall Ph.D. (Director and Head) (Director and Head)

Rights and permissions

Reprints and permissions

Copyright information

© 1999 Springer Basel AG

About this chapter

Cite this chapter

Tramposch, K.M. (1999). Skin inflammation. In: Morgan, D.W., Marshall, L.A. (eds) In Vivo Models of Inflammation. Progress in Inflammation Research. Birkhäuser, Basel. https://doi.org/10.1007/978-3-0348-7775-6_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-0348-7775-6_8

  • Publisher Name: Birkhäuser, Basel

  • Print ISBN: 978-3-0348-7777-0

  • Online ISBN: 978-3-0348-7775-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation